Tumefactive multiple sclerosis lesions under fingolimod treatment

Neurology. 2012 Nov 6;79(19):2000-3. doi: 10.1212/WNL.0b013e3182735cb3. Epub 2012 Oct 3.

Authors

Femke Visser¹, Mike P Wattjes, Petra J W Pouwels, Wim H J P Linssen, Bob W van Oosten

Affiliation

¹ Department of Neurology, Sint Lucas Andreas Hospital, Amsterdam, the Netherlands. [email protected]

PMID: 23035065
DOI: 10.1212/WNL.0b013e3182735cb3

No abstract available

Publication types

Case Reports

MeSH terms

Aspartic Acid / analogs & derivatives
Aspartic Acid / metabolism
Brain / pathology*
Choline / metabolism
Female
Fingolimod Hydrochloride
Humans
Immunosuppressive Agents / therapeutic use*
Inositol / metabolism
Magnetic Resonance Imaging
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / pathology*
Nerve Fibers, Myelinated / pathology*
Propylene Glycols / therapeutic use*
Sphingosine / analogs & derivatives*
Sphingosine / therapeutic use
Young Adult

Substances

Immunosuppressive Agents
Propylene Glycols
Aspartic Acid
Inositol
N-acetylaspartate
Fingolimod Hydrochloride
Choline
Sphingosine